Black Hawk Acquisition (BKHA) vs LeonaBio (LONA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
LeonaBio is the larger company by market cap ($54.2 million vs $47.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BKHA | LONA |
|---|---|---|
| Share price | $11.53 | $5.75 |
| Market cap | $47.89M | $54.17M |
| 1-day change | -6.49% | 0.00% |
| YTD return | — | -24.04% |
| 1-year return | — | +46.68% |
| 5-year return | — | -93.99% |
| P/E ratio (TTM) | 34.94 | — |
| EPS (TTM) | $0.33 | $-23.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.15 | $14.21 |
| 52-week low | $11.00 | $2.21 |
| Distance from 52-week high | -12.32% | -59.54% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +201.39% |
| Average volume | 5.92K | 185.45K |
| Shares outstanding | 4.15M | 9.42M |
| Employees | — | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Black Hawk Acquisition
BKHA stock →Black Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About LeonaBio
LONA stock →LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
BKHA vs LONA FAQ
Which is bigger, Black Hawk Acquisition or LeonaBio?
LeonaBio (LONA) is larger, with a market capitalization of $54.17M compared with $47.89M for Black Hawk Acquisition (BKHA).
Are Black Hawk Acquisition and LeonaBio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.